

I. In The Claims:

Applicant elects the invention of Group I and as specifically required to elect a single disclosed species from Claim 2 if Group I is elected, Applicant elects the species pancreas.

1. (Original) A vaccine for cancer immunotherapy comprising a monoclonal antibody directed to a cancer cell and transfer factor wherein the monoclonal antibody is conjugated to an antigen.

2. (Original) The vaccine according to claim 1 wherein the cancer cell is selected from the group consisting of lung, pancreas, liver, cervical, kidney, brain, breast and spleen cancers.

3. (Original) The vaccine according to claim 2 wherein the cancer cell is a pancreas cancer cell.

4. (Original) The vaccine according to claim 1 wherein the antigen is asp f l.

5. (Original) The vaccine according to claim 1 wherein the antigen is the mumps virus.

6. (Original) The vaccine according to claim 1 wherein the monoclonal antibody is selected from the group consisting of 17-1A, CC49, EGFr surface factor, anti MC-10 antigen, anti-HER2, anti- CD20, NR-LU-10 and MDX-H210.

Claims 7-11: Currently cancelled.

12. (Original) A composition comprising the vaccine of claim 1, for use in a method of treatment of cancer in a human body; said method comprising: administering to said human said monoclonal antibody and said transfer factor in separate steps.

Claims 13-19: Currently cancelled.

20. (Original) A cancer immunotherapy kit comprising a monoclonal antibody wherein the monoclonal antibody further includes an antigen and transfer factor.

21. (Original) The kit according to claim 24 wherein the antigen is asp f 1 .